MeiraGTx (NASDAQ:MGTX) Insider Stuart Naylor Sells 27,659 Shares

Posted by Geri Gentry on Jul 8th, 2026

MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) insider Stuart Naylor sold 27,659 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $14.80, for a total transaction of $409,353.20. Following the sale, the insider directly owned 640,846 shares of the company’s stock, valued at approximately $9,484,520.80. This trade represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

MeiraGTx Price Performance

NASDAQ:MGTX opened at $14.66 on Wednesday. The business’s 50-day moving average is $10.41 and its two-hundred day moving average is $8.89. The firm has a market capitalization of $1.36 billion, a PE ratio of -9.91 and a beta of 1.20. MeiraGTx Holdings PLC has a 12 month low of $6.62 and a 12 month high of $15.35.

MeiraGTx (NASDAQ:MGTX – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04. The company had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $17.00 million. Equities analysts anticipate that MeiraGTx Holdings PLC will post -1.55 EPS for the current year.

Institutional Investors Weigh In On MeiraGTx

A number of institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new position in MeiraGTx in the first quarter worth about $557,000. Rhumbline Advisers lifted its holdings in MeiraGTx by 9.4% during the 2nd quarter. Rhumbline Advisers now owns 63,715 shares of the company’s stock worth $415,000 after buying an additional 5,488 shares during the last quarter. Brown Advisory Inc. bought a new position in MeiraGTx during the 2nd quarter worth approximately $326,000. Qube Research & Technologies Ltd acquired a new position in shares of MeiraGTx in the 2nd quarter worth approximately $530,000. Finally, Quantinno Capital Management LP acquired a new position in shares of MeiraGTx in the 2nd quarter worth approximately $319,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

Wall Street Analyst Weigh In

MGTX has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a research report on Tuesday, April 21st. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of MeiraGTx in a report on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating on shares of MeiraGTx in a research note on Tuesday, May 26th. Wall Street Zen upgraded MeiraGTx from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Finally, Piper Sandler increased their price target on MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, MeiraGTx presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.83.

View Our Latest Research Report on MGTX

MeiraGTx Company Profile

(Get Free Report)

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.